ISTH 2020 Congress Archives - ISTH Congress Abstracts

Abstract Number: LB/CO01.1

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

P. Chowdary^1,2, S. Shapiro³, M. Makris⁴, G. Evans⁵, S. Boyce⁶, K. Talks⁷, G. Dolan⁸, U. Reiss⁹, M. Phillips¹, A. Riddell¹, M.R. Peralta¹, M. Quaye², E. Tuddenham¹, J. Krop¹⁰, G. Short¹¹, S. Kar¹¹, A. Smith¹¹, A. Nathwani^1,2
Abstract Number: LB/CO01.2

Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States

H. Al-Samkari^1,2, S. Gupta^2,3, R. Karp Leaf^1,2, W. Wang⁴, R. Rosovsky^1,2, K. Bauer^2,5, D. Leaf^2,3, STOP-COVID Investigators
Abstract Number: LB/CO01.3

Incidence of Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalisation

M.M. Engelen, T. Vanassche, T. Balthazar, E. Claeys, J. Gunst, M. Jacquemin, S. Janssens, N. Lorent, L. Liesenborghs, K. Peerlinck, G. Pieters, S. Rex, P. Sinonquel, L. Van der Linden, C. Van Laer, R. Vos, J. Wauters, A. Wilmer, P. Verhamme, C. Vandenbriele
Abstract Number: LB/CO01.4

Higher Incidence of Thrombotic Complications in Hospitalized Patients with SARS-COV-2 Virus versus Influenza Virus Infections

M.A.M. Stals¹, M.J.J.H. Grootenboers², C. van Guldener³, F.H.J. Kaptein¹, S.J.E. Braken¹, Q. Chen⁴, G. Chu¹, E.M. van Driel⁵, A. Iglesias del Sol⁶, F. Pals¹, M.M.A. Toorop⁴, S.C. Cannegieter^1,4, F.A. Klok¹, M.V. Huisman¹
Abstract Number: OC 01.1

von Willebrand Factor as a Predictor of Mortality and its Target Concentration Dependent Inhibition by BT200 Aptamer in Patients Treated with Potent ADP Receptor Blockers

K. Kovacevic¹, B. Jilma¹, S. Zhu², J. C. Gilbert², M.-P. Winter³, A. Toma³, I. Lang³, C. Hengstenberg³, J. Siller-Matula⁴
Abstract Number: OC 01.2

Low-grade Endotoxaemia Enhances Artery Thrombus Growth via Toll-like Receptor 4: Implication for Myocardial Infarction

C. Nocella¹, R. Carnevale², S. Sciarretta², V. Cammisotto², V. Valenti², C. Calvieri², G. Frati², G. D'Amati², R. Cangemi², A. Arrivi³, M. Dominici³, E. Mangeri², C. Gaudio², G. Tanzilli², F. Violi²
Abstract Number: OC 01.3

Unraveling the Protective Effects of Factor Xa Inhibition by Rivaroxaban on Atherosclerosis by RNA Sequencing

J.J. Posma¹, R. Van Oerle¹, A.C. Cleuren², M.A. Van der Ent², A. Isaacs³, M. Stoll^4,5, H. Ten Cate^1,6, H.M. Spronk¹
Abstract Number: OC 01.4

Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression

M. Lenz¹, C. Kaun¹, A. Rehberger², M. Sebestjen², C. Binder³, K. Huber⁴, C. Hengstenberg¹, J. Wojta¹, W. Speidl¹, P. Hohensinner¹
Abstract Number: OC 01.5

Impact of Platelet-Selective TGF-β1-Deficiency in Atherogenesis and CD4+ T Effector Responses Using a No-Germline Genetic Engineering Atherosclerosis Mouse Model

S. Tan¹, Y. Sun², A. Gisterå¹, Y. Min¹, J. Zhang¹, C. Ma², N. Li¹
Abstract Number: OC 02.1

Fibrin γ-chain Crosslinking Plays an Important Role in Preventing Thrombus Breakdown and Embolisation in-vivo

C. Duval¹, A. Baranauskas¹, M. Ali¹, Z. Raslan¹, S.R. Baker¹, H.R. McPherson¹, M.A. Bailey¹, R.M. Cubbon¹, R.A. Ajjan¹, H. Philippou¹, K.K. Naseem¹, V.C. Ridger², R.A.S. Ariëns¹
Abstract Number: OC 02.2

Chemical Modulation of Fibrinogen Production and its Impact on Venous Thrombosis

R. Vilar¹, S.W. Lukowski², M. Garieri¹, C. Di Sanza¹, M. Neerman-Arbez^1,3, R.J. Fish¹
Abstract Number: OC 02.3

FXIII Catalyses Histone-Fibrin Crosslinking to Inhibit Fibrinolysis

M. Locke, C. Longstaff
Abstract Number: OC 02.4

Fibrinogen Is Citrullinated in Venous Thrombi and Forms Fragile Clots with Increased Resistance to Lysis

I. Varju^1,2,3, N. Sorvillo^2,4, D. Cherpokova^2,4, V.J. Farkas¹, A.Z. Farkas¹, E. Komorowicz¹, T. Feller⁵, B. Kiss⁵, M.S. Kellermayer⁵, L. Szabo⁶, A. Wacha⁷, A. Bota⁷, C. Longstaff⁸, D.D. Wagner^2,4,9, K. Kolev¹
Abstract Number: OC 02.5

Low α2-plasmin Inhibitor Antigen Levels on Admission Predict Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis

R. Orbán-Kálmándi¹, B. Baráth¹, F. Sarkady¹, E. Székely¹, I. Szegedi², K.R. Czuriga-Kovács², I. Fekete², K. Fekete², É. Katona¹, L. Csiba², Z. Bagoly^1,3
Abstract Number: OC 03.1

Immune Profiling of Previously Untreated Patients with Severe Haemophilia A by High-throughput Mimotope Variation Analysis

G. Baselli¹, R. Palla², C. Valsecchi³, K. Palm⁴, S. Miri⁵, F. Peyvandi^2,3, SIPPET Study Group
Abstract Number: OC 03.2

Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A

C. Königs¹, M.C. Ozelo², A. Dunn³, R. Kulkarni⁴, B. Nolan⁵, S.A. Brown⁶, R. Liesner⁷, M. Schiavulli⁸, S. Gunawardena⁹, S. Mukhopadhyay¹⁰, D. Jayawardene⁹, B. Winding¹¹, M. Carcao¹²
Abstract Number: OC 03.3

Deciphering the Ets-1/2-mediated Transcriptional Regulation of F8 Gene Identifies a Minimal F8 Promoter for Hemophilia A Gene Therapy

R. Famà¹, E. Borroni¹, S. Merlin¹, S. Pignani¹, C. Airoldi², A. Cucci¹, V. Bruscaggin¹, S. Scardellato¹, M. Pinotti³, G.E. Walker¹, A. Follenzi¹
Abstract Number: OC 03.4

First In Human Liver Biopsy Study Following Gene Therapy for Hemophilia A

S. Fong¹, S. Rangarajan², N. Mitchell¹, C.-R. Sihn¹, B. Yates¹, R. Torres¹, C. Russell¹, K.J. Pasi³, A. Lawal¹, B. Kim¹, S. Bunting¹, G. Pierce⁴, W.Y. Wong¹
Abstract Number: OC 03.5

Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A

L. George^1,2, E. Eyster³, M. Ragni⁴, S. Sullivan⁵, B. Samelson-Jones^1,2, M. Evans³, A. MacDougall⁶, M. Curran⁶, S. Tompkins⁶, K. Wachtel⁶, D. Takefman⁶, K. Reape⁶, F. Mingozzi⁶, P. Monahan⁶, X. Anguela⁶, K. High⁶
Abstract Number: OC 04.1

Moderate Platelet Defects but Efficiently Restored Thrombopoietin Production Early after Partial Hepatectomy via JAK2-STAT3 Signaling in Mice

F. Reusswig¹, N. Fazel Modares², M. Brechtenkamp³, I. Krueger³, D. Herebian⁴, D. Häussinger⁵, J. Scheller², M. Elvers³